Premium
Dengue Fever, COVID ‐19 ( SARS‐CoV ‐2), and Antibody‐Dependent Enhancement ( ADE ): A Perspective
Author(s) -
Ulrich Henning,
Pillat Micheli M.,
Tárnok Attila
Publication year - 2020
Publication title -
cytometry part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.316
H-Index - 90
eISSN - 1552-4930
pISSN - 1552-4922
DOI - 10.1002/cyto.a.24047
Subject(s) - dengue fever , antibody dependent enhancement , dengue virus , antibody , virology , covid-19 , virus , coronavirus , vero cell , flow cytometry , pandemic , immunology , biology , medicine , infectious disease (medical specialty) , disease , pathology
Abstract SARS‐CoV‐2 pandemic and recurrent dengue epidemics in tropical countries have turned into a global health threat. While both virus‐caused infections may only reveal light symptoms, they can also cause severe diseases. Here, we review the possible antibody‐dependent enhancement (ADE) occurrence, known for dengue infections, when there is a second infection with a different virus strain. Consequently, preexisting antibodies do not neutralize infection, but enhance it, possibly by triggering Fcγ receptor‐mediated virus uptake. No clinical data exist indicating such mechanism for SARS‐CoV‐2, but previous coronavirus infections or infection of SARS‐CoV‐2 convalescent with different SARS‐CoV‐2 strains could promote ADE, as experimentally shown for antibodies against the MERS‐CoV or SARS‐CoV spike S protein. © 2020 International Society for Advancement of Cytometry